Search

Your search keyword '"Biological products industry -- Product development"' showing total 382 results
Start Over Descriptor "Biological products industry -- Product development" Journal m2 pharma
382 results on '"Biological products industry -- Product development"'

1. Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044

Subjects
Biological products industry -- Product development, Biopharmaceutics -- Product development, Lung cancer, Non-small cell, Clinical trials, Chemistry
Abstract

M2 PHARMA-January 3, 2025-Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044 (C)2025 M2 COMMUNICATIONS Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday the [...]

Published
2025

2. Hansa Biopharma reports positive Phase 2 imlifidase results

Subjects
Biological products industry -- Product development, Guillain-Barre syndrome -- Prognosis -- Research, Nervous system diseases -- Prognosis -- Research, Chemistry
Abstract

M2 PHARMA-December 18, 2024-Hansa Biopharma reports positive Phase 2 imlifidase results (C)2024 M2 COMMUNICATIONS Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) on Tuesday announced positive full results from the 15-HMedIdeS-09 single [...]

Published
2024

3. Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome

Subjects
Biological products industry -- Product development, Viral antibodies, Clinical trials, Antibodies, Chemistry
Abstract

M2 PHARMA-December 3, 2024-Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome (C)2024 M2 COMMUNICATIONS Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) and Genethon, a developer of gene therapies [...]

Published
2024

4. LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval

Subjects
Biological products industry -- Product development, Patient compliance, Clinical trials, Vaccines -- Product development, Rabies, Chemistry
Abstract

M2 PHARMA-October 28, 2024-LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval (C)2024 M2 COMMUNICATIONS Biopharmaceutical company LakeShore Biopharma Co., Ltd (Nasdaq: LSB) announced on Friday [...]

Published
2024

5. Pharming initiates Phase II clinical trial for leniolisib in PIDs

Subjects
Euronext Amsterdam N.V. -- Product development, Pharming Group N.V. -- Product development, Product development, Securities industry, Clinical trials, Securities industry -- Product development, Internet fraud, Biological products industry -- Product development, Phishing
Abstract

M2 PHARMA-October 10, 2024-Pharming initiates Phase II clinical trial for leniolisib in PIDs (C)2024 M2 COMMUNICATIONS Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Thursday that it has [...]

Published
2024

6. FDA clears IND for Compugen's COM503 triggering USD30m milestone

Subjects
Gilead Sciences Inc. -- Product development, Compugen Ltd. -- Product development, Biological products industry -- Product development, Protein binding, Biotechnology industry -- Product development, Chemistry
Abstract

M2 PHARMA-July 29, 2024-FDA clears IND for Compugen's COM503 triggering USD30m milestone (C)2024 M2 COMMUNICATIONS Clinical-stage therapeutic discovery and development company Compugen Ltd. (Nasdaq:CGEN) (TASE:CGEN) announced on Monday the FDA [...]

Published
2024

7. Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996

Subjects
Genentech Inc. -- Product development, Roche Holding AG -- Product development, Biological products industry -- Product development, Biotechnology industry -- Product development, Clinical trials, Chemistry
Abstract

M2 PHARMA-July 17, 2024-Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996 (C)2024 M2 COMMUNICATIONS Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: [...]

Published
2024

8. Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial

Subjects
Dynavax Technologies Corp. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Clinical trials, Vaccines -- Product development, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-June 28, 2024-Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial (C)2024 M2 COMMUNICATIONS Dynavax Technologies Corporation (Nasdaq: DVAX), a California-based commercial-stage biopharmaceutical company, announced on Thursday that [...]

Published
2024

9. Palatin Technologies initiates Phase 2 bremelanotide clinical study to treat obesity

Subjects
Palatin Technologies Inc. -- Product development, Biological products industry -- Product development, Obesity -- Care and treatment, Intermedin, Clinical trials, Chemistry
Abstract

M2 PHARMA-June 13, 2024-Palatin Technologies initiates Phase 2 bremelanotide clinical study to treat obesity (C)2024 M2 COMMUNICATIONS Palatin Technologies, Inc. (NYSE American: PTN), a US-based biopharmaceutical company developing first-in-class medicines [...]

Published
2024

10. Arcus Biosciences announces completion of enrollment in Phase 3 trial for domvanalimab regimen in upper GI cancers

Subjects
Gilead Sciences Inc. -- Product development, Biological products industry -- Product development, Chemotherapy, Cancer -- Chemotherapy, Chemistry
Abstract

M2 PHARMA-June 10, 2024-Arcus Biosciences announces completion of enrollment in Phase 3 trial for domvanalimab regimen in upper GI cancers (C)2024 M2 COMMUNICATIONS Clinical-stage biopharmaceutical company Arcus Biosciences Inc (NYSE:RCUS) [...]

Published
2024

11. Xeris Biopharma reports positive Phase 2 data for XP-8121

Subjects
United States. Food and Drug Administration -- Planning, Biological products industry -- Product development, Hypothyroidism, Company business planning, Chemistry
Abstract

M2 PHARMA-May 30, 2024-Xeris Biopharma reports positive Phase 2 data for XP-8121 (C)2024 M2 COMMUNICATIONS Biopharmaceutical company Xeris Biopharma Holdings Inc (Nasdaq:XERS) on Thursday reported positive topline results from its [...]

Published
2024

13. HanAll Biopharma initiates Phase III VELOS-4 Trial for dry eye treatment

Subjects
Biological products industry -- Product development, Eye diseases, Clinical trials, Chemistry
Abstract

M2 PHARMA-May 3, 2024-HanAll Biopharma initiates Phase III VELOS-4 Trial for dry eye treatment (C)2024 M2 COMMUNICATIONS Biopharmaceutical company HanAll Biopharma Co., Ltd. (KRX:009420) announced on Friday that it has [...]

Published
2024

14. Kiromic BioPharma announces positive results in Deltacel-01 trial for NSCLC treatment

Subjects
United States. Food and Drug Administration -- Planning, Biological products industry -- Product development, Lung cancer, Non-small cell -- Care and treatment, Clinical trials, Company business planning, Chemistry
Abstract

M2 PHARMA-April 24, 2024-Kiromic BioPharma announces positive results in Deltacel-01 trial for NSCLC treatment (C)2024 M2 COMMUNICATIONS Biotherapeutics company Kiromic BioPharma (OTCQB: KRBP) on Wednesday reported consistent favourable safety, tolerability, [...]

Published
2024

15. YS Biopharma's YS-HBV-002 receives Philippine clinical trial approval

Subjects
Biological products industry -- Product development, Hepatitis B -- Health aspects, Drug approval -- Health aspects, Clinical trials -- Health aspects, Vaccines -- Product development, Chemistry
Abstract

M2 PHARMA-April 19, 2024-YS Biopharma's YS-HBV-002 receives Philippine clinical trial approval (C)2024 M2 COMMUNICATIONS YS Biopharma Co., Ltd. (Nasdaq: YS), a China-based global biopharmaceutical company, announced on Thursday that it [...]

Published
2024

18. Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial

Subjects
Psoriasis, Biological products industry -- Product development, Chemistry
Abstract

M2 PHARMA-February 14, 2024-Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial (C)2024 M2 COMMUNICATIONS Artax Biopharma Inc, a US-based clinical-stage biotechnology company, announced on Tuesday that it [...]

Published
2024

19. YS Biopharma completes enrolment for PIKA Rabies Vaccine phase three clinical trial

Subjects
Biological products industry -- Product development, Clinical trials, Vaccines -- Product development, Rabies, Chemistry
Abstract

M2 PHARMA-November 1, 2023-YS Biopharma completes enrolment for PIKA Rabies Vaccine phase three clinical trial (C)2023 M2 COMMUNICATIONS YS Biopharma Co Ltd (NASDAQ: YS), a China-based global biopharmaceutical company, announced [...]

Published
2023

20. Kiromic BioPharma collaborates with Beverly Hills Cancer Center for Deltacel clinical trial

Subjects
Biological products industry -- Product development, Clinical trials, Lung cancer, Non-small cell, Cancer, Chemistry
Abstract

M2 PHARMA-October 23, 2023-Kiromic BioPharma collaborates with Beverly Hills Cancer Center for Deltacel clinical trial (C)2023 M2 COMMUNICATIONS Biotherapeutics company Kiromic BioPharma (OTC PINK: KRBP) declared on Monday that it [...]

Published
2023

21. Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention

Subjects
Gilead Sciences Inc. -- Product development, Biological products industry -- Product development, HIV (Viruses), Sexually transmitted diseases -- Prevention, Clinical trials, Chemistry
Abstract

M2 PHARMA-October 18, 2023-Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention (C)2023 M2 COMMUNICATIONS Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Wednesday the [...]

Published
2023

22. Transgene and BioInvent evaluate BT-001 oncolytic virus in combination trial with KEYTRUDA

Subjects
Merck & Company Inc. -- Product development, Euronext Paris S.A. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Securities industry -- Product development, Pharmaceutical industry -- Product development, Securities industry, Chemistry, Keytruda (Medication) -- Product development
Abstract

M2 PHARMA-October 10, 2023-Transgene and BioInvent evaluate BT-001 oncolytic virus in combination trial with KEYTRUDA (C)2023 M2 COMMUNICATIONS Biotechnology companies Transgene (Euronext Paris: TNG) and BioInvent International AB (Nasdaq Stockholm: [...]

Published
2023

23. YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial

Subjects
Biological products industry -- Product development, Clinical trials, Vaccines -- Product development, Rabies, Chemistry
Abstract

M2 PHARMA-September 27, 2023-YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial (C)2023 M2 COMMUNICATIONS YS Biopharma Co., Ltd. (NASDAQ: YS), a China-based global biopharmaceutical company, [...]

Published
2023

24. Valneva and Pfizer report positive paediatric and adolescent Phase 2 booster results for Lyme disease vaccine candidate

Subjects
Pfizer Inc. -- Product development, Valneva SE -- Product development, Euronext Paris S.A. -- Product development, Biological products industry -- Product development, Pediatrics -- Reports, Biotechnology industry -- Product development, Vaccines -- Product development, Lyme disease -- Reports, Securities industry -- Product development, Pharmaceutical industry -- Product development, Securities industry, Chemistry
Abstract

M2 PHARMA-September 7, 2023-Valneva and Pfizer report positive paediatric and adolescent Phase 2 booster results for Lyme disease vaccine candidate (C)2023 M2 COMMUNICATIONS Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) [...]

Published
2023

25. BioCity Biopharma doses first patient in BC3195 Phase 1a/1b clinical trial in China

Subjects
Biological products industry -- Product development, Biological products -- Product development, Clinical trials, Chemistry
Abstract

M2 PHARMA-July 20, 2023-BioCity Biopharma doses first patient in BC3195 Phase 1a/1b clinical trial in China (C)2023 M2 COMMUNICATIONS BioCity Biopharma, a China-based clinical-stage biopharmaceutical company, announced on Wednesday that [...]

Published
2023

26. BioCity Biopharma enrols two subjects with IgA nephropathy for Phase 2 trial of SC0062

Subjects
Biological products industry -- Product development, Chronic kidney failure, Immunoglobulin A, Clinical trials, Chemistry
Abstract

M2 PHARMA-June 22, 2023-BioCity Biopharma enrols two subjects with IgA nephropathy for Phase 2 trial of SC0062 (C)2023 M2 COMMUNICATIONS BioCity Biopharma, a China-based clinical-stage biopharmaceutical company, announced on Wednesday [...]

Published
2023

27. First Participant Vaccinated in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Subjects
Biological products industry -- Product development, Vaccination, Influenza vaccines -- Evaluation -- Product development, Viral antibodies, Influenza, Clinical trials, Antibodies, Chemistry
Abstract

M2 PHARMA-June 16, 2023-First Participant Vaccinated in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs (C)2023 M2 COMMUNICATIONS - The first participant has been vaccinated in France-based biopharmaceutical company [...]

Published
2023

28. Bavarian Nordic reports 12-month durability data from Phase 2 COVID-19 booster vaccine trial

Subjects
Bavarian Nordic A/S -- Product development, Biological products industry -- Product development, Clinical trials, Vaccines -- Product development, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-June 16, 2023-Bavarian Nordic reports 12-month durability data from Phase 2 COVID-19 booster vaccine trial (C)2023 M2 COMMUNICATIONS Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) on Friday released the [...]

Published
2023

29. Geron initiates Phase 2 IMpress trial for Imetelstat in relapsed/refractory AML and higher risk MDS patients

Subjects
Geron Corp. -- Product development, Biological products industry -- Product development, Stem cells, Clinical trials, Chemistry
Abstract

M2 PHARMA-June 13, 2023-Geron initiates Phase 2 IMpress trial for Imetelstat in relapsed/refractory AML and higher risk MDS patients (C)2023 M2 COMMUNICATIONS Biopharmaceutical company Geron Corporation (Nasdaq: GERN) on Tuesday [...]

Published
2023

30. Palatin Technologies reports presentation of preclinical data on diabetic nephropathy

Subjects
Palatin Technologies Inc. -- Product development, Biological products industry -- Product development, Diabetic nephropathies, Chemistry
Abstract

M2 PHARMA-May 30, 2023-Palatin Technologies reports presentation of preclinical data on diabetic nephropathy (C)2023 M2 COMMUNICATIONS Palatin Technologies (NYSE American: PTN), a biopharmaceutical company focused on developing receptor-specific product candidates [...]

Published
2023

31. Transgene and BioInvent's oncolytic virus BT-001 shows positive Phase Ia results in solid tumour treatment

Subjects
Euronext Paris S.A. -- Product development, Biological products industry -- Product development, Securities industry -- Product development, Securities industry, Chemistry
Abstract

M2 PHARMA-May 25, 2023-Transgene and BioInvent's oncolytic virus BT-001 shows positive Phase Ia results in solid tumour treatment (C)2023 M2 COMMUNICATIONS Biotechnology companies Transgene (Euronext Paris:TNG) and BioInvent International AB [...]

Published
2023

33. Genentech's Fenebrutinib shows positive results in Phase II study for multiple sclerosis, reducing brain lesions compared to placebo

Subjects
Genentech Inc. -- Product development, Roche Holding AG -- Product development, Brain -- Comparative analysis, Brain damage -- Comparative analysis, Biological products industry -- Product development, Multiple sclerosis -- Comparative analysis, Biotechnology industry -- Product development, B cells -- Comparative analysis, Clinical trials -- Comparative analysis, Chemistry
Abstract

M2 PHARMA-May 17, 2023-Genentech's Fenebrutinib shows positive results in Phase II study for multiple sclerosis, reducing brain lesions compared to placebo (C)2023 M2 COMMUNICATIONS Neuroscience research company Genentech, a member [...]

Published
2023

34. First Patient Dosed for Phase 1 Clinical Trial of Anti-CD39xTGF-I[superscript two] Bispecific Antibody ES014

Subjects
Biological products industry -- Product development, Biological products -- Product development, Viral antibodies, Clinical trials, Transforming growth factors, Antibodies, Chemistry
Abstract

M2 PHARMA-March 6, 2023-First Patient Dosed for Phase 1 Clinical Trial of Anti-CD39xTGF-β Bispecific Antibody ES014 (C)2023 M2 COMMUNICATIONS - The first patient has been dosed in a Phase 1 [...]

Published
2023

35. Pharming Group enrols first patient in Phase III leniolisib clinical trial

Subjects
Euronext Amsterdam N.V. -- Product development, Pharming Group N.V. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, B cells, Clinical trials, Securities industry -- Product development, Securities industry, Chemistry
Abstract

M2 PHARMA-February 22, 2023-Pharming Group enrols first patient in Phase III leniolisib clinical trial (C)2023 M2 COMMUNICATIONS Pharming Group NV (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR), a Netherlands-based global biopharmaceutical company, [...]

Published
2023

36. WestVac Biopharma claims 'significant progress' in COVID-19 vaccine development against latest prevalent subvariants

Subjects
Biological products industry -- Product development, Vaccines -- Product development, Recombinant proteins, Chemistry
Abstract

M2 PHARMA-February 21, 2023-WestVac Biopharma claims 'significant progress' in COVID-19 vaccine development against latest prevalent subvariants (C)2023 M2 COMMUNICATIONS China-based WestVac Biopharma (Guangzhou) Co., Ltd., has claimed that with the [...]

Published
2023

37. Pharming enrolls first paediatric patient in leniolisib clinical trial

Subjects
Euronext Amsterdam N.V. -- Product development, Pharming Group N.V. -- Product development, Biological products industry -- Product development, Internet fraud, Phishing, B cells, Clinical trials, Securities industry -- Product development, Securities industry, Chemistry
Abstract

M2 PHARMA-February 21, 2023-Pharming enrolls first paediatric patient in leniolisib clinical trial (C)2023 M2 COMMUNICATIONS Biopharmaceutical company Pharming Group N.V. (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) disclosed on Tuesday that it [...]

Published
2023

38. Pfizer and Valneva stops Lyme disease vaccine trial at some sites

Subjects
Pfizer Inc. -- Product development, Valneva SE -- Product development, Euronext Paris S.A. -- Product development, Biological products industry -- Product development, Biotechnology industry -- Product development, Clinical trials, Vaccines -- Product development, Lyme disease, Securities industry -- Product development, Pharmaceutical industry -- Product development, Securities industry, Chemistry
Abstract

M2 PHARMA-February 17, 2023-Pfizer and Valneva stops Lyme disease vaccine trial at some sites (C)2023 M2 COMMUNICATIONS US biopharmaceutical company Pfizer Inc (NYSE:PFE) and vaccine company Valneva SE (Nasdaq:VALN) (Euronext [...]

Published
2023

39. VBI Vaccines reports interim data from Phase 2 study evaluating combination of VBI-2601 (BRII-179) and BRII-835 to treat chronic Hepatitis

Subjects
Biological products industry -- Product development, Hepatitis B, Vaccines -- Product development, Chemistry
Abstract

M2 PHARMA-February 15, 2023-VBI Vaccines reports interim data from Phase 2 study evaluating combination of VBI-2601 (BRII-179) and BRII-835 to treat chronic Hepatitis B (C)2023 M2 COMMUNICATIONS Biopharmaceutical company VBI [...]

Published
2023

40. Valneva completes recruitment for Phase 3 trial of chikungunya vaccine candidate in adolescents

Subjects
Valneva SE -- Product development -- Recruiting, Euronext Paris S.A. -- Product development -- Recruiting, Biological products industry -- Product development, Vaccination, Biotechnology industry -- Product development, Clinical trials, Vaccines -- Product development, Securities industry -- Product development, Industry hiring, Securities industry, Chemistry
Abstract

M2 PHARMA-February 14, 2023-Valneva completes recruitment for Phase 3 trial of chikungunya vaccine candidate in adolescents (C)2023 M2 COMMUNICATIONS Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) announced on Tuesday that [...]

Published
2023

41. Immix Biopharma reports dosing of first patients in trial of IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination

Subjects
Novartis AG -- Product development, Biological products industry -- Product development, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-February 7, 2023-Immix Biopharma reports dosing of first patients in trial of IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination (C)2023 M2 COMMUNICATIONS Biopharmaceutical company Immix Biopharma Inc (ImmixBio) (Nasdaq:IMMX) announced [...]

Published
2023

42. Genexine DNA Vaccine for Advanced Cervical Cancer Receives Fast Track Designation from Korean Health Authority

Subjects
Merck & Company Inc. -- Product development, Biological products industry -- Product development, DNA, Food -- Safety and security measures, DNA vaccines, Cervical cancer -- Drug therapy, Cancer -- Genetic aspects, Clinical trials, Cancer vaccines -- Product development, Chemistry
Abstract

M2 PHARMA-January 24, 2023-Genexine DNA Vaccine for Advanced Cervical Cancer Receives Fast Track Designation from Korean Health Authority (C)2023 M2 COMMUNICATIONS - Clinical-staged Korean biopharmaceutical company Genexine (KOSDAQ: 095700) has [...]

Published
2023

43. Palatin Technologies commences phase 2b bremelanotide clinical trial

Subjects
Palatin Technologies Inc. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Intermedin, Clinical trials, Chemistry
Abstract

M2 PHARMA-January 20, 2023-Palatin Technologies commences phase 2b bremelanotide clinical trial (C)2023 M2 COMMUNICATIONS Palatin Technologies, Inc. (NYSE American: PTN), a US-based biopharmaceutical company, announced on Thursday that it has [...]

Published
2023

44. Jiangsu Recbio Technology's REC610 shingles vaccine clinical trial application receives Philippines regulatory approval

Subjects
Biological products industry -- Product development, Medical research, Medicine, Experimental, Clinical trials, Vaccines -- Product development, Chemistry
Abstract

M2 PHARMA-December 19, 2022-Jiangsu Recbio Technology's REC610 shingles vaccine clinical trial application receives Philippines regulatory approval (C)2022 M2 COMMUNICATIONS Jiangsu Recbio Technology Co., Ltd., a China-based vaccine company, together with [...]

Published
2022

45. Lyvgen Biopharma enters collaborates with Bristol Myers Squibb for LVGN7409 phase two randomised trial in Combination with Nivolumab

Subjects
Biological products industry -- Product development, Lung cancer, Non-small cell, Monoclonal antibodies, Chemistry
Abstract

M2 PHARMA-November 28, 2022-Lyvgen Biopharma enters collaborates with Bristol Myers Squibb for LVGN7409 phase two randomised trial in Combination with Nivolumab (C)2022 M2 COMMUNICATIONS Lyvgen Biopharma, a China-based global biotech [...]

Published
2022

46. VBI Vaccines Initiates Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

Subjects
Biological products industry -- Product development, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Clinical trials -- Health aspects, Proteins -- Health aspects, Coronaviruses -- Health aspects, Chemistry
Abstract

M2 PHARMA-September 29, 2022-VBI Vaccines Initiates Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901 (C)2022 M2 COMMUNICATIONS - US-based biopharmaceutical company VBI Vaccines Inc. (NASDAQ: VBIV) has started enrollment [...]

Published
2022

47. Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug

Subjects
Biogen Inc. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Biological products -- Product development, Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, Clinical trials, Belimumab -- Product development, Chemistry
Abstract

M2 PHARMA-September 16, 2022-Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug (C)2022 M2 COMMUNICATIONS - US-based healthcare provider Northwell Health's Division of Rheumatology and The [...]

Published
2022

48. Dynavax Technologies Corporation doses first subject in rF1V vaccine trial

Subjects
United States. Department of Defense, Dynavax Technologies Corp. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Clinical trials, Vaccines -- Product development, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-September 13, 2022-Dynavax Technologies Corporation doses first subject in rF1V vaccine trial (C)2022 M2 COMMUNICATIONS Dynavax Technologies Corporation ( Nasdaq: DVAX), a commercial-stage biopharmaceutical company, announced on Monday in [...]

Published
2022

49. Can-Fite BioPharma announces clinical trial for Piclidenoson to treatment osteoarthritis in dogs

Subjects
Can-Fite BioPharma Ltd. -- Product development, Biological products industry -- Product development, Antiarthritic agents -- Product development, Dogs, Clinical trials, Osteoarthritis, Pharmaceutical industry -- Product development, Chemistry
Abstract

M2 PHARMA-August 17, 2022-Can-Fite BioPharma announces clinical trial for Piclidenoson to treatment osteoarthritis in dogs (C)2022 M2 COMMUNICATIONS Biotechnology company Can-Fite BioPharma Ltd (NYSE American: CANF) (TASE: CFBI) revealed on [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results